Published on : Apr 07, 2016
ALBANY, New York, April 07, 2016: The global breast cancer market is set for rapid growth in the next few years due to active product developments and innovations. Breast cancer, which develops in breast tissues, can be identified via signs such as a lump in the breast, dimpling of the skin, a change in the shape of breasts, or a red scaly patch of skin. Obesity, drinking alcohol, lack of exercise, and family history are some of the risk factors associated with breast cancer. Breast cancer commonly develops in cells from the lining of milk ducts. The outcome of breast cancer varies and depends on the type of cancer, the patient’s age, and the extent of the disease. Some of the best ways to reduce the risk of breast cancer are drinking less alcohol, maintaining a healthy weight, and being physically active.
The global breast cancer market is expected to expand in the years to come due to the increasing pool of women diagnosed with breast cancer and the increasing breast cancer treatments in the pipeline. Currently, leading players in the global breast cancer market are planning many innovations to increase their share in the market in the years to come. Diversification of molecular targets will benefit the global market for breast cancer. Also, the growing opportunities for biological products and innovative first-in-class product developments remain two of the major avenues predicted to benefit the global breast cancer market.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=668359
In the coming few years, changes in the commercial and clinical environment are expected to be favorable for leading players to target their niche products to patients. Sustained innovations in breast cancer treatments and drugs are further predicted to contribute towards the growth of the global breast cancer market in the next few years.
The current unmet needs in the global breast cancer market are expected to create growth opportunities for leading players. The entry of new companies and their innovations is also expected to propel the global market for breast cancer. The assessment of pipeline products and innovative breast cancer treatments prove that the global market is set for rapid growth. Currently, with 1,050 products in active development stages, the breast cancer pipeline is a major segment of the global pharmaceutical industry. The report identifies 333 first-in-class programs in the active breast cancer pipeline, with 251 first-in-class molecular targets. Roughly around 289 first-in-class products in the development phase have not yet been involved in co-development or licensing deals. This is expected to create numerous product licensing opportunities in the global market, which is expected to propel the global breast cancer market in the years to come.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]